Maintenance of Viral Suppression after Optimization Therapy from Etravirine Plus Raltegravir to Rilpivirine Plus Dolutegravir in HIV-1-Infected Patients

Non-nucleoside reverse-transcriptase inhibitor plus integrase strand transfer inhibitor–based dual therapies are an attractive simplification, nucleoside reverse transcriptase inhibitor-sparing strategy for experienced human immunodeficiency virus-infected patients. Thus, we performed a 24-week real...

Descripción completa

Detalles Bibliográficos
Autores principales: Riccardi, Niccolò, Del Puente, Filippo, Taramasso, Lucia, Di Biagio, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6748463/
https://www.ncbi.nlm.nih.gov/pubmed/30798670
http://dx.doi.org/10.1177/2325958218821657
_version_ 1783452095637094400
author Riccardi, Niccolò
Del Puente, Filippo
Taramasso, Lucia
Di Biagio, Antonio
author_facet Riccardi, Niccolò
Del Puente, Filippo
Taramasso, Lucia
Di Biagio, Antonio
author_sort Riccardi, Niccolò
collection PubMed
description Non-nucleoside reverse-transcriptase inhibitor plus integrase strand transfer inhibitor–based dual therapies are an attractive simplification, nucleoside reverse transcriptase inhibitor-sparing strategy for experienced human immunodeficiency virus-infected patients. Thus, we performed a 24-week real-life observational study to assess efficacy and safety of switching from raltegravir plus etravirine to dolutegravir plus rilpivirine in 7 previously heavily treated patients. This simplification strategy reduced pill burden and preserved viral suppression in treatment-experienced patients with no major mutations to rilpivirine at historical genotyping.
format Online
Article
Text
id pubmed-6748463
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-67484632019-11-04 Maintenance of Viral Suppression after Optimization Therapy from Etravirine Plus Raltegravir to Rilpivirine Plus Dolutegravir in HIV-1-Infected Patients Riccardi, Niccolò Del Puente, Filippo Taramasso, Lucia Di Biagio, Antonio J Int Assoc Provid AIDS Care Case Report Non-nucleoside reverse-transcriptase inhibitor plus integrase strand transfer inhibitor–based dual therapies are an attractive simplification, nucleoside reverse transcriptase inhibitor-sparing strategy for experienced human immunodeficiency virus-infected patients. Thus, we performed a 24-week real-life observational study to assess efficacy and safety of switching from raltegravir plus etravirine to dolutegravir plus rilpivirine in 7 previously heavily treated patients. This simplification strategy reduced pill burden and preserved viral suppression in treatment-experienced patients with no major mutations to rilpivirine at historical genotyping. SAGE Publications 2019-01-07 /pmc/articles/PMC6748463/ /pubmed/30798670 http://dx.doi.org/10.1177/2325958218821657 Text en © The Author(s) 2019 http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Case Report
Riccardi, Niccolò
Del Puente, Filippo
Taramasso, Lucia
Di Biagio, Antonio
Maintenance of Viral Suppression after Optimization Therapy from Etravirine Plus Raltegravir to Rilpivirine Plus Dolutegravir in HIV-1-Infected Patients
title Maintenance of Viral Suppression after Optimization Therapy from Etravirine Plus Raltegravir to Rilpivirine Plus Dolutegravir in HIV-1-Infected Patients
title_full Maintenance of Viral Suppression after Optimization Therapy from Etravirine Plus Raltegravir to Rilpivirine Plus Dolutegravir in HIV-1-Infected Patients
title_fullStr Maintenance of Viral Suppression after Optimization Therapy from Etravirine Plus Raltegravir to Rilpivirine Plus Dolutegravir in HIV-1-Infected Patients
title_full_unstemmed Maintenance of Viral Suppression after Optimization Therapy from Etravirine Plus Raltegravir to Rilpivirine Plus Dolutegravir in HIV-1-Infected Patients
title_short Maintenance of Viral Suppression after Optimization Therapy from Etravirine Plus Raltegravir to Rilpivirine Plus Dolutegravir in HIV-1-Infected Patients
title_sort maintenance of viral suppression after optimization therapy from etravirine plus raltegravir to rilpivirine plus dolutegravir in hiv-1-infected patients
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6748463/
https://www.ncbi.nlm.nih.gov/pubmed/30798670
http://dx.doi.org/10.1177/2325958218821657
work_keys_str_mv AT riccardiniccolo maintenanceofviralsuppressionafteroptimizationtherapyfrometravirineplusraltegravirtorilpivirineplusdolutegravirinhiv1infectedpatients
AT delpuentefilippo maintenanceofviralsuppressionafteroptimizationtherapyfrometravirineplusraltegravirtorilpivirineplusdolutegravirinhiv1infectedpatients
AT taramassolucia maintenanceofviralsuppressionafteroptimizationtherapyfrometravirineplusraltegravirtorilpivirineplusdolutegravirinhiv1infectedpatients
AT dibiagioantonio maintenanceofviralsuppressionafteroptimizationtherapyfrometravirineplusraltegravirtorilpivirineplusdolutegravirinhiv1infectedpatients

Ejemplares similares